GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

GEV.US

1,062.39

-1.55%↓

286.82

+2.31%↑

RTX

174.1

-1.22%↓

224.38

+1.39%↑

UNP

263.93

+0.03%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.79 3.47

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.78

Максимум

1.79

Ключови измерители
By Trading Economics
Приходи	2.3M -18M
Продажби	-1.9M -193K
Марж на печалбата	9,174.093
Служители	116
EBITDA	1.5M -16M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+566.49% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-8.7M 626M
Предишно отваряне	-1.68
Предишно затваряне	1.79

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.05.2026 г., 23:43 ч. UTC

Значими събития в новините

New Zealand's Unemployment Rate Falls in 1Q

5.05.2026 г., 23:20 ч. UTC

Горещи акции

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5.05.2026 г., 21:48 ч. UTC

Печалби

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5.05.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6.05.2026 г., 00:00 ч. UTC

Пазарно говорене

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5.05.2026 г., 22:26 ч. UTC

Пазарно говорене

AMD Data-Center Business Continues to Surge -- Market Talk

5.05.2026 г., 22:20 ч. UTC

Пазарно говорене

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5.05.2026 г., 22:08 ч. UTC

Печалби

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5.05.2026 г., 22:07 ч. UTC

Печалби

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5.05.2026 г., 21:48 ч. UTC

Печалби

Pan American Silver 1Q Rev $1.2B >PAAS

5.05.2026 г., 21:42 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:38 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:30 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:29 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:26 ч. UTC

Печалби

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q EPS 39c >ALC.EB

5.05.2026 г., 21:25 ч. UTC

Печалби

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5.05.2026 г., 21:24 ч. UTC

Печалби

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5.05.2026 г., 21:18 ч. UTC

Печалби

Mistras Backs 2026 Rev $730M-$750M >MG

5.05.2026 г., 21:17 ч. UTC

Печалби

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5.05.2026 г., 21:15 ч. UTC

Печалби

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5.05.2026 г., 21:12 ч. UTC

Печалби

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5.05.2026 г., 21:11 ч. UTC

Печалби

SSR Mining 1Q Rev $581.8M >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q Adj EPS $1.15 >SSRM

5.05.2026 г., 21:10 ч. UTC

Печалби

SSR Mining 1Q EPS $1.16 >SSRM

5.05.2026 г., 21:08 ч. UTC

Печалби

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5.05.2026 г., 21:01 ч. UTC

Печалби

Intact Financial 1Q EPS C$4.12 >IFC.T

5.05.2026 г., 21:01 ч. UTC

Горещи акции

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

566.49% нагоре

12-месечна прогноза

Среден 12.33 USD 566.49%

Висок 22 USD

Нисък 8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.